Covidien revamps revenue reporting, warns foreign exchange rates will hurt; J&J/DePuy rolls out new elbow prosthesis system;

@FierceMedDev: Mindray climbs back from damage done on Twitter. Article | Follow @FierceMedDev

@MarkHFierce: Solta Medical, an aesthetic med device maker with sagging sales, will sell itself for $250M. Reorganization wasn't enough. Story | Follow @MarkHFierce

@MichaelGFierce: To deliver drugs, German engineers took a cue from some of the best swimmers in nature: sperm cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Here's what 21 tweets can do to your reputation: Mindray climbs back from damage done on Twitter. More | Follow @GalenMoore

> Covidien ($COV) is revamping how it reports revenue from its various business segments, and the company also warns that foreign exchange rates could negatively affect its fiscal 2014 guidance. Item

> Johnson & Johnson's ($JNJ) DePuy Synthes division is launching a new prosthesis system in the U.S. for joint replacement in the elbow. Item

> A long-time executive credited with building Varian Medical Systems' ($VAR) X-Ray Products division is retiring this February. Item

> Corgenix said it has made its 510(k) submission with the FDA for its TxBCardio urine test. Item

> InVivo Therapeutics has brought in a veteran Biomet executive as its interim chief financial officer. Item

Biotech News

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Why is it a CEO can't be fired or quit? Amarin's Joe Z "retires." joins a long list of biotech retirees who either jumped or were pushed. More | Follow @JohnCFierce

@DamianFierce: Genentech wrote a solid guide to some of the methodology used in the much-discussed I-SPY 2 studies. More from Genetech | Follow @DamianFierce

@EmilyMFierce: Booster of red blood cells synthesized for first time. Story via SciAm | Follow @EmilyMFierce

> Cubist bounces along with more promising PhIII antibiotic results. News

> AcelRx spikes on $250M deal for late-stage pain drug/device Zalviso. More

> CEO of troubled Amarin heads for the exit as FDA readies Vascepa decision. Article

> Agenus mounts a comeback on positive results for its brain cancer vaccine. Story

Pharma News

@FiercePharma:  Endo to Acquire Specialty Pharmaceutical Company NuPathe. Release | Follow @FiercePharma

@EricPFierce: Bloomberg says drugmakers make catch a break on in Germany, price cuts and rebates may fall next year. More | Follow @EricPFierce

@CarlyHFierce: Sanofi signs on to sell Vivus ED drug in emerging markets. Friday's story | Follow @CarlyHFierce

> China rounds up counterfeiters as the FDA boosts its oversight there. More

> GlaxoSmithKline bets another $1B on India with stake-raising buyout offer. News

> More new drugs, yes. Lots more sales? Not always, thanks to skeptical payers. Story

CRO News

> Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug. Story

> Quotient Clinical is the latest CRO snapped up by private equity. Report

> Belgian CRO Genae reaches into Switzerland for medical device work. News

> Bayer teams up with Texas' MD Anderson for cancer clinical trials. More

> Charles River shakes up its leadership to cut costs and boost sales. Article

> CROS NT names a new CEO amid its global push. Item

Biotech IT News

> Twitter-driven stock furor prompts exchange to fine Medivir. More

> Court fines Boehringer $1M for 'gross inadequacy' of record keeping. News

> Merck turns to gamification to help Type 2 diabetics. Article

> Accelrys inks $50M Qumas takeover to continue deal-driven expansion. Report

> BGI is building a huge genome database to drive drug discovery. Story

> NIH names its first associate director of data science. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.